Petrylak, D. P., Kuo, P. H., Gravis, G., hacker, M., Gao, X., Kanesvaran, R., Wilmot, C., Duan, J., Caparica, R., Dorff, T. B. (2026). The LuxAR-02 phase II study of luxdegalutamide in combination with [
                    <sup>177</sup>
                    Lu]Lu-PSMA-617 in patients with prostate-specific membrane antigen (PSMA)–positive metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.tps278